{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.3","upperLimit":"95.7","value":"66.7"},{"groupId":"OG001","lowerLimit":"29.0","upperLimit":"93.3","value":"71.4"},{"groupId":"OG002","lowerLimit":"35.5","upperLimit":"66.7","value":"51.2"},{"groupId":"OG003","lowerLimit":"17.2","upperLimit":"59.3","value":"36.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"43"},{"groupId":"OG003","value":"22"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"ND Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2-6: 240 mg iv Days 1, 15 Cycle 7 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1\n\nPomalidomide:\n\n4 mg po daily (Days 1-21) of each 28-day cycle\n\nDexamethasone:\n\nWeeks without daratumumab dosing 40 mg po per day (Days 1, 8, 15, 22) of each 28-day cycle for subjects 75 years old 20 mg po per day (Days 1, 8, 15, 22) of each 28-day cycle for subjects \\> 75 years old","id":"OG000","title":"Cohort A-1"},{"description":"ND-Pd Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2-6: 240 mg iv Days 1, 15 Cycle 7 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG001","title":"Cohort A-2"},{"description":"ND Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1\\*-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG002","title":"Cohort B-1"},{"description":"D Monotherapy Regimen\n\nEach cycle is 28 days\n\nDaratumumab:\n\nCycle 1\\*-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG003","title":"Cohort B-2"}],"paramType":"NUMBER","populationDescription":"All randomized participants in the nivo dara cohort","reportingStatus":"POSTED","timeFrame":"approximately up to 4 years","title":"Objective Response Rate in the Nivolumab + Daratumumab Cohort","type":"SECONDARY","unitOfMeasure":"Percentage"}